• Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • Pre- and post-diagnostic beta-blocker use and lung cancer survival: A population-based cohort study.Abstract

    Beta-blockers have been associated with decreased cancer mortality. However, evidence for lung cancer is sparse and reported beneficial effects might be based on biased analyses. In this so far largest study we investigated the association betweeneta-blocker use and lung cancer survival. Therefore, patients with a lung cancer diagnosis between April 1998 and December 2011 were selected from a database linkage of the Netherlands Cancer Registry and the PHARMO Database Network

    Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel Mppv, Vissers PAJ, Brenner H. Sci Rep. 2017 Jun 06; 7 2911.
  • Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.Abstract

    Recent experimental and epidemiological studies have suggested that beta blocker use might be associated with better cancer prognosis, but results were inconclusive and only few studies have investigated the association specifically for colorectalancer (CRC) patients. We investigated this hypothesis using a linked dataset of the Eindhoven area of the Netherlands Cancer Registry and the PHARMO record linkage, including patients diagnosed with CRC between 1998 and 2011

    Jansen L, Weberpals J, Kuiper JG, Vissers PA, Wolkewitz M, Hoffmeister M, Brenner H. Int J Cancer. 2017 Apr 01; 62-71.
  • Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation.Abstract

    Type 2 diabetes mellitus (T2DM) is associated with greater risk for colorectal cancer (CRC). The age of onset of T2DM is decreasing worldwide. An increased CRC risk in young T2DM patients could be relevant for the age at which to initiate CRC screeing. We report on CRC risk in T2DM patients with attention to age of diagnosis

    deKort S, Masclee AAM, Sanduleanu S, Weijenberg MP, van Herk-Sukel MPP, Olden hof NJJ, van den Bergh JPW, Haak HR, Janssen-Heijnen ML. Sci Rep. 2017 Apr 24; 7 46527.
  • Impact of detection bias on the risk of gastrointestinal cancer and its subsites in type 2 diabetes mellitus.Abstract

    BACKGROUND: Type 2 diabetes mellitus (T2DM) may be a risk factor for gastrointestinal (GI) cancers, but variations in study designs of observational studies may have yielded biased results due to detection bias. Furthermore, differences in risk forGI cancer subsites have not been extensively evaluated

    deJong RGPJ, Burden AM, deKort S, van Herk-Sukel MPP, Vissers PAJ, Janssen PKC, Haak HR, Masclee AAM, deVries F, Janssen-Heijnen MLG. Eur J Cancer. 2017 Apr 29; 79 61-71.
  • No decreased risk of gastrointestinal cancers in users of metformin in The Netherlands; a time-varying analysis of metformin exposure.Abstract

    Previous studies on metformin use and gastrointestinal (GI) cancer risk have yielded inconclusive results on metformin’s chemoprotective effects. We aimed to evaluate GI cancer risk in users of metformin in The Netherlands using a time-varying apprach in a large population-based database. A cohort study was performed using the NCR-PHARMO database

    deJong RG, Burden AM, deKort S, van Herk-Sukel M, Vissers PA, Janssen PK, Haak HR, Masclee AA, deVries F, Janssen-Heijnen ML. Cancer Prev Res (Phila). 2017 Mar 08;
  • Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes.Abstract

    Information on treatment patterns for ovarian cancer (OC) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for OC in the Netherlands and evaluate survival outcomes following subsequentlines of treatment. Data from the Eindhoven Cancer Registry, including on newly diagnosed cancer patients, were linked to the PHARMO Database Network, including information on in- and out-patient drug use

    Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, Severens JL, van Herk-Sukel MP. Med Oncol. 2017 Apr; 34 (4): 50.
  • No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.Abstract

    Several studies have suggested an association between use of metformin and an increased overall survival in patients diagnosed with pancreatic cancer, however with several important methodological limitations. The aim of the study was to assess theassociation between overall survival, pancreatic cancer, and metformin use

    Frouws MA, Mulder BG, Bastiaannet E, Zander s MM, van Herk-Sukel MP, deLeede EM, Bonsing BA, Mieog JS, VandeVelde CJ, Liefers GJ. Medicine (Baltimore). 2017 Mar; 96 (10): e6229.
  • The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.Abstract

    BACKGROUND: Several studies have suggested that the association between aspirin and improved cancer survival is mediated through the mechanism of aspirin as thrombocyte aggregation inhibitors (TAI). The aim of this study was to provide epidemiologial evidence for this mechanism assessing the association between overall survival and the use of aspirin and non-aspirin TAI in patients with colorectal cancer

    Frouws MA, Rade maker E, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, Vande Velde CJ, Portielje JE, Liefers GJ. Eur J Cancer. 2017 Mar 25; 77 24-30.
  • Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia Patients.Abstract

    Kuiper J, Musingarimi P, Tapprich C, Penning-van Beest F, Gaudig M. J Clin Intensive Care Med. 2017 2 025-033.
  • Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.Abstract

    BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patientwith gastrointestinal tract cancer. METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included

    Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Vande Velde CJ, Portielje JE, Liefers GJ. Br J Cancer. 2017 Jan; 116 (3): 405-413.